
|Articles|March 31, 2008
FDA requires REMS plan for 25 drugs, biologics
FDA issues a notice requiring the manufacturers of 25 high-risk drugs and biologics to submit a REMS plan.
Advertisement
In a notice published in the March 27
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
National Pharmacist Day: Pharmacist, Educator Details Evolution of Scope of Practice
2
Additional Steps in Prescribing Limit RSV Vaccine Access
3
First OTC Pill for Birth Control Significantly Advances Health Equity
4
CPAs Give Community Pharmacists More Active Roles in Health Care
5










































































































































































































